A Study of Lebrikizumab in Adults With Nummular Eczema
← catalyst calendarNCT07542483 · readout ≤ 743 d
Sponsored by Almirall, S.A. (industry) · ALM.MC — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
270estimated
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-24 | actual | When the study began enrolling |
| Primary completion | Aug 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Nummular Eczema
Interventions
- Drug: Lebrikizumab
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants Achieving Investigator Global Assessment (IGA) Score of 0 or 1 and a >=2-point Reduction from Baseline at Week 24
measured Baseline, Week 24
Permalink · ALM.MC's whole pipeline · Catalyst calendar · Every registered study · What changed